Stay updated with breaking news from Products Grants Program. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
/PRNewswire/ -- Cumberland Pharmaceuticals Inc. (NASDAQ: CPIX), a specialty pharmaceutical company, today announced significantly improved financial results...
In a break with past precedent, last year’s Food and Drug Administration (FDA) user fee reauthorization legislation did not contain significant FDA policy changes. Although the Senate...
These measures follow the successful passage of H.R. 6833 in October, which included a five-year reauthorization of critical FDA user-fee programs that help ensure rare disease patients gain timely access to essential therapies and diagnostic tools.
The fund will back clinical trials, natural history studies, and regulatory science tools that will give the FDA a greater understanding of the ways that rare diseases can be treated.
SILVER SPRING, Md., Oct. 17, 2022 /PRNewswire/ -- Today, the U.S. Food and Drug Administration announced it has awarded 19 new grants and two new contracts totaling more than $38